Roth Capital Believes 'Panic Has Created Some Compelling Opportunities on the Long Side' in Biotech; Highlights bluebird bio, Cempra, MacroGenics, Sarepta, uniQure, Nektar, PTC Therapeutics
Paul Quintaro